How Analyte Specific Reagents Support Quality in Research and Diagnostic Labs

In both research and diagnostic laboratories, the integrity of data—and by extension, clinical decision-making—depends heavily on the reagents used. Variability in antibody binding, staining intensity, and background signal can compromise accuracy and draw out workflows by requiring repeat testing. 

Analyte specific reagents (ASRs) are defined by the FDA as reagents, including antibodies, receptor proteins, ligands, nucleic acid sequences, and similar materials that, through specific binding or chemical reactions, identify and quantify specific analytes within biological specimens. ASR antibodies, in particular, are foundational components of laboratory-developed tests (LDTs) and are regulated by the FDA under 21 CFR 864.4020. ASR antibodies play a critical role in offering the quality needed to support compliance and ensure reliable and efficient testing across diverse laboratory environments. 

Regulatory framework of ASRs

A majority of ASRs are classified as Class I medical devices and are regulated under the FDA’s current good manufacturing practices, as outlined in 21 CFR Part 820, with additional requirements for labeling, sale, distribution, and use under 21 CFR 809.10(e) and 21 CFR 809.30.¹ In cases where ASRs are intended for higher-risk applications, such as blood banking, donor screening, and some infectious disease testing, they are classified as Class II or Class III medical devices, which carry additional regulatory requirements.^1,2

ASRs are intended for use by in vitro diagnostic manufacturers, CLIA-certified clinical laboratories, and other organizations developing tests for non-diagnostic purposes such as forensic, academic, and research laboratories. As per the FDA’s guidance, ASR manufacturers are also prohibited from providing instructions for use in a particular test, and from making any claims regarding the analytical or clinical performance of the ASR.¹

This regulatory framework distinguishes ASR antibodies from research use only (RUO) antibodies. RUO antibodies are not subject to regulatory requirements or good manufacturing practices (GMPs), making them suitable for basic and applied research rather than diagnostic workflows. In contrast, ASRs must be manufactured in compliance with 21 CFR Part 820. While not required by the FDA, ASR manufacturers may also seek ISO 13485:2016 certification and participate in the Medical Device Single Audit Program (MDSAP) to align with international standards and further ensure product quality and regulatory compliance.^3,4

Key quality considerations

Lot-to-lot consistency is a critical factor in the selection and use of ASR antibodies. Variability across production batches can affect staining intensity, background signal, and binding specificity, compromising test reliability and necessitating recalibration. To deliver the level of consistency required in regulated workflows, manufacturers must employ robust quality control systems, standardize manufacturing protocols, and maintain comprehensive and readily available documentation, including certificates of analysis and technical data sheets. This directly translates to fewer test failures, reduced recalibration needs, and more consistent diagnostic interpretations. 

Even when sourcing from a trusted supplier, successful ASR use requires thoughtful integration. The antibody’s properties must align with the laboratory’s intended use. In multiplex flow cytometry-based assays, for example, antibodies should exhibit high sensitivity and specificity with minimal cross-reactivity. Additionally, fluorochrome conjugates should exhibit limited spectral overlap to reduce spillover and the need for complex compensation. 

Some additional factors to consider include clone specificity and buffer formulation. Clone specificity determines which epitope the antibody will recognize and bind to. Using a well-characterized and validated clone that detects the epitope of interest reduces the risk of cross-reactivity and improves reliability. When it comes to buffer formulation, components such as stabilizers, preservatives, and proteins can influence staining quality, instrument compatibility, and assay performance. Laboratories must verify whether the buffer is compatible with their intended assay and won’t interfere with downstream steps. 

Finally, laboratories developing LDTs must validate test performance using the selected ASRs for parameters such as accuracy, precision, sensitivity, and specificity.⁵ High-quality reagents, combined with deliberate integration and proper validation, provide a strong foundation for maintaining compliance and ensuring reproducible results. 

Supporting research and diagnostic workflows

ASR antibodies facilitate testing across both clinical and research environments. In clinical laboratories, ASRs serve as the building blocks of LDTs used in high-complexity applications, such as flow cytometry. LDTs are in vitro diagnostic products designed, manufactured, and used within a single CLIA-certified laboratory that meets the regulatory requirements to perform high complexity testing. These tests often inform patient treatment and are generally developed to target analytes for which commercial tests are not available.

In translational research settings, the quality and consistency of ASRs offer advantages over RUO alternatives. Due to the strong manufacturing controls in place for ASRs, researchers can be confident that observed changes reflect true biological variation. This is especially valuable in studies that compare samples across time points or between cohorts, such as biomarker discovery and validation, as well as in longitudinal studies.

Another advantage of using ASRs in research is that they can facilitate a smooth transition between research and clinical implementation. By incorporating ASRs early in assay development, research labs can simplify the transition to LDTs for clinical use, avoiding the need to substitute reagents, re-optimize protocols, and repeat validation studies. For labs developing assays with future clinical potential, adopting ASRs from the start can reduce time, resource usage, and risk later in the process. 

Maximize ASR value with automation

Workflow automation is becoming increasingly essential in high-complexity clinical laboratories, particularly for complex applications like flow cytometry. When paired with ASRs, automation further enhances reproducibility and quality while also improving throughput and operational efficiency. 

Automated reagent preparation systems, especially those with integrated barcode tracking, help eliminate common sources of error, including sample mix-ups, transcription errors, and pipetting inconsistencies, resulting in more consistent and reliable results. Beyond error reduction, automation supports ergonomic improvements by minimizing repetitive manual tasks. This reduces the risk of repetitive strain injuries and burnout, contributing to a safer and more positive working environment. 

Automation also supports the optimized utilization of limited resources, like lab staff. In the face of widespread staffing shortages, automation of routine tasks enables laboratories to maintain or even expand testing volumes without increasing headcount or compromising quality. Importantly, it also allows skilled personnel to focus on more complex, value-added tasks. 

Conclusion

ASRs are foundational in supporting the quality, consistency, and reliability that flow cytometry and other high-complexity applications depend on. From regulatory alignment to manufacturing rigor, ASR antibodies support the development of LDTs that deliver reproducible and dependable results. 

Sourcing ASRs from trusted suppliers like BioLegend, a part of Revvity, further strengthens this foundation. BioLegend supplies ASR antibodies that are manufactured in ISO 13485:2016 and MDSAP-certified facilities, in accordance with 21 CFR Part 820, offering the quality and documentation necessary to meet both regulatory and performance expectations. 

These high-quality reagents help laboratories increase throughput, minimize errors, and make the most of available resources, thereby supporting operational excellence and high standards of patient care. When paired with automation solutions like the Fontus™ Workstation from Revvity, workflows can be further optimized, as the Fontus system offers easy-to-use software, optimized deck access, verified protocols, and reformatting capabilities. 

To learn more about ASRs and automation, visit https://www.biolegend.com/en-us/clinical-flow-cytometry.

References

1. “Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/commercially-distributed-analyte-specific-reagents-asrs-frequently-asked-questions
2. “§ 864.4020 Analyte specific reagents.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-864/subpart-E/section-864.4020
3. “ISO 13485:2016(en).” https://www.iso.org/obp/ui#iso:std:iso:13485:ed-3:v1:en
4. “Medical Device Single Audit Program (MDSAP).” https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap
5. “Regulatory Knowledge Guide for Laboratory Developed Tests.” https://seed.nih.gov/sites/default/files/2024-04/Regulatory-Knowledge-Guide-for-Laboratory-Developed-Tests.pdf